Lasofoxifene Effective for Dyspareunia

Article

Dyspareunia is a significant problem in postmenopausal women. A recent study at George Washington University found that up to 92% of sexually active women reported moderate or severe symptoms. Forty percent of women cited dyspareunia as their most bothersome problem associated with vaginal atrophy. A recent Phase III trial showed that lasofoxifene can significantly improve the symptoms of dyspareunia as well as increase bone mineral density (BMD) in postmenopausal women.

Recent Videos
Mitchell Creinin, MD, reports estetrol pill eases menstrual symptoms | Image Credit: health.ucdavis.edu
1 expert is featured in this series.
Susanna Mitro, PhD, reveals ethnic disparities in uterine fibroid diagnosis | Image Credit: divisionofresearch.kaiserpermanente.org.
Shayna Mancuso, DO, highlights the real impact of menopause | Image Credit: linkedin.com.
Jihong Liu, ScD, explains how to improve perinatal outcomes in COVID patients | Image Credit: sc.edu.
1 expert is featured in this series.
Jihong Liu, ScD, highlights adverse perinatal outcomes linked to the COVID pandemic | Image Credit: sc.edu.
Experts highlight infant health benefits from minor diet changes in pregnancy | Image Credit: ohsu.edu.
Connie Stark, RNC, PNC, provides fertility preservation insights for endometriosis patients | Image Credit: linkedin.com.
How the impact of maternal diet on infant health is strengthened in late pregnancy | Image Credit: ohsu.edu.
Related Content
© 2025 MJH Life Sciences

All rights reserved.